PARP Inhibitors in the Management of Ovarian Cancer

Repeating PARPi therapy in the treatment of epithelial ovarian cancer (EOC) is NOT recommended at this time. Consideration should be made as to the best time in the life cycle of an individual patient’s EOC in which to use PARPi. Clinical trial participation is encouraged. ( IC , Ins , B , S )